Isomorphic Labs
Isomorphic Labs funding: the Series C round announced on 17 November 2026, from the company’s own announcement.
- Amount
- $5 billion
- Round
- Series C
- Announced
- Led by
- Greenoaks, Sequoia Capital (co-leads)
- Category
- AI models and agents
Isomorphic Labs announced a $5 billion Series C on 17 November 2026, co-led by Greenoaks and Sequoia Capital. Isomorphic Labs, based in London, is an AI company focused on designing and developing new medicines with its proprietary drug design engine, IsoDDE. Other investors named in the announcement: Andreessen Horowitz, Alphabet, Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.
Use of funds. Mature IsoDDE, expand into new biology with more advanced models, build AI-led bioengineering infrastructure and take its drug candidates toward clinical trials.
Questions
How much did Isomorphic Labs raise?
$5 billion in a Series C, announced on 17 November 2026.
Who led Isomorphic Labs’ round?
Greenoaks and Sequoia Capital (co-leads).
What does Isomorphic Labs do?
Isomorphic Labs designs and develops new medicines with AI, using its drug design engine IsoDDE for internal programs and with partners.
See every round in the tech funding tracker, and read what a funding round does not tell you.
- Company
- Isomorphic Labs
- Amount, USD million
- 5,000
- Other investors
- Andreessen Horowitz (a16z), Alphabet, Thrive Capital, MGX, GV, CapitalG, Temasek, UK Sovereign AI Fund
- Headquarters
- United Kingdom
- Announcement
- prnewswire.com
- Sources
Source Link Isomorphic Labs announcement https://www.prnewswire.com/news-releases/isomorphic-labs-announces-5-billion-series-c-funding-302942062.html
Source: amounts, rounds, lead investors and valuations are as stated in the company’s or lead investor’s own announcement, linked under Sources on each round’s page.
